bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 3 from Restoration of miR17/20a in Solid Tumor Cells Enhances the Natural Killer Cell Antitumor Activity by Targeting Mekk2
Authors: Jiang Hong , Wang Ping , Li Xiaohua , Wang Qilong , Deng Zhong-Bin , Zhuang Xiaoying , Mu Jingyao , Zhang Lifeng , Wang Baomei , Yan Jun , Miller Donald , Zhang Huang-Ge
Published: April 2023

PDF file - 23K, Figure S3. Map3k2 is a direct target of miR-17/20a as predicted by public algorithms.
Supplementary Figure 2 from Restoration of miR17/20a in Solid Tumor Cells Enhances the Natural Killer Cell Antitumor Activity by Targeting Mekk2
Authors: Jiang Hong , Wang Ping , Li Xiaohua , Wang Qilong , Deng Zhong-Bin , Zhuang Xiaoying , Mu Jingyao , Zhang Lifeng , Wang Baomei , Yan Jun , Miller Donald , Zhang Huang-Ge
Published: April 2023

PDF file - 27K, Figure S2. Reduction of MHC class I expression on tumor cells elicited by miR-17/20a.
Supplementary Table 1 from TCR Sequencing Can Identify and Track Glioma-Infiltrating T Cells after DC Vaccination
Authors: Hsu Melody S. , Sedighim Shaina , Wang Tina , Antonios Joseph P. , Everson Richard G. , Tucker Alexander M. , Du Lin , Emerson Ryan , Yusko Erik , Sanders Catherine , Robins Harlan S. , Yong William H. , Davidson Tom B. , Li Gang , Liau Linda M. , Prins Robert M.
Published: April 2023

Clinical patient characteristics
Supplementary Figure 1 from TCR Sequencing Can Identify and Track Glioma-Infiltrating T Cells after DC Vaccination
Authors: Hsu Melody S. , Sedighim Shaina , Wang Tina , Antonios Joseph P. , Everson Richard G. , Tucker Alexander M. , Du Lin , Emerson Ryan , Yusko Erik , Sanders Catherine , Robins Harlan S. , Yong William H. , Davidson Tom B. , Li Gang , Liau Linda M. , Prins Robert M.
Published: April 2023

Supplementary Figure 1 shows representative IHC staining of TIL to confirm that these T cells are found in the parenchyma of the tumor and not tumor blood vessels.
Supplementary Figure 2 from Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab
Authors: Shreders Amanda , Joseph Richard , Peng Chengwei , Ye Fei , Zhao Shilin , Puzanov Igor , Sosman Jeffrey A. , Johnson Douglas B.
Published: April 2023

Progression free survival and overall survival using alternate cutoffs for prolonged benefit ({greater than or equal to} 67% percentile) and rapid progression (< 33 percentile).
Supplementary Figure 1 from Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab
Authors: Shreders Amanda , Joseph Richard , Peng Chengwei , Ye Fei , Zhao Shilin , Puzanov Igor , Sosman Jeffrey A. , Johnson Douglas B.
Published: April 2023

Progression free survival and overall survival using alternate cutoffs for prolonged benefit ({greater than or equal to} 120 days) and rapid progression (< 60 days).
Supplementary Figure 3 from Inhibition of Soluble Tumor Necrosis Factor Prevents Chemically Induced Carcinogenesis in Mice
Authors: Sobo-Vujanovic Andrea , Vujanovic Lazar , DeLeo Albert B. , Concha-Benavente Fernando , Ferris Robert L. , Lin Yan , Vujanovic Nikola L.
Published: April 2023

MCA and TNF-exclusion don't affect Tregs. Splenocytes were simultaneously stained with anti-CD4-FITC and anti-CD25-PE mAb, fixed, permeabilized, stained with anti-FoxP3-APC mAb, and examined by flow cytometry. (A) Gating strategies: Gate 1, single cells; Gate 2, mononuclear cells; Gate 3A, two-color analyses of CD4+and CD25+ mononuclear cells; Gate 3B, two-color analyses of CD4+ and FoxP3+ mononuclear cells; and Gate 4, three-color analysis of CD4+CD25+FoxP3+ mononuclear cells. (B) Bar-graph presents individual data of three separate experiments (one day 14, and two day 84 after MCA injection) showing percentages of CD4+CD25+ (blue bars), CD4+FoxP3+ (green bars) and CD4+CD25+FoxP3+ (red bars) Tregs.
Supplementary Figure 4 from In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates
Authors: Wang Changyu , Thudium Kent B. , Han Minhua , Wang Xi-Tao , Huang Haichun , Feingersh Diane , Garcia Candy , Wu Yi , Kuhne Michelle , Srinivasan Mohan , Singh Sujata , Wong Susan , Garner Neysa , Leblanc Heidi , Bunch R. Todd , Blanset Diann , Selby Mark J. , Korman Alan J.
Published: April 2023

PDF file - 239K, Figure S4. A, Expression of PD-1 in CD4 T cells during mixed lymphocyte reaction (MLR). B, Expression of PD-1 and PD-L1 during stimulation of peripheral blood mononuclear cells (PBMC) by superantigen SEB.
Supplementary Figure 3 from In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates
Authors: Wang Changyu , Thudium Kent B. , Han Minhua , Wang Xi-Tao , Huang Haichun , Feingersh Diane , Garcia Candy , Wu Yi , Kuhne Michelle , Srinivasan Mohan , Singh Sujata , Wong Susan , Garner Neysa , Leblanc Heidi , Bunch R. Todd , Blanset Diann , Selby Mark J. , Korman Alan J.
Published: April 2023

PDF file - 22K, Figure S3. Nivolumab inhibits PD-1 interaction with PD-L1 and PD-L2.
Supplementary Figure S2 from A Paracrine Role for IL6 in Prostate Cancer Patients: Lack of Production by Primary or Metastatic Tumor Cells
Authors: Yu Shu-Han , Zheng Qizhi , Esopi David , Macgregor-Das Anne , Luo Jun , Antonarakis Emmanuel S. , Drake Charles G. , Vessella Robert , Morrissey Colm , De Marzo Angelo M. , Sfanos Karen S.
Published: April 2023

IL-6 mRNA positive blood vessels in prostate cancer bone metastases. Example of IL-6 positive endothelial cells and IL-6 negative metastatic tumor cells in prostate cancer bone metastases.
Supplementary Table 1 from STING Ligand c-di-GMP Improves Cancer Vaccination against Metastatic Breast Cancer
Authors: Chandra Dinesh , Quispe-Tintaya Wilber , Jahangir Arthee , Asafu-Adjei Denise , Ramos Ilyssa , Sintim Herman O. , Zhou Jie , Hayakawa Yoshihiro , Karaolis David K.R. , Gravekamp Claudia
Published: April 2023

PDF file - 62K, Table S1A: Effect of c-di-GMP on immune cells in 4T1 tumors. Table S1B: Effect of c-di-GMP on immune cells in spleens of 4T1 tumor-bearing mice. Table S1C: Effect of c-di-GMP on immune cells in lymph nodes of 4T1 tumor-bearing mice.
Supplementary Figure 9 from STING Ligand c-di-GMP Improves Cancer Vaccination against Metastatic Breast Cancer
Authors: Chandra Dinesh , Quispe-Tintaya Wilber , Jahangir Arthee , Asafu-Adjei Denise , Ramos Ilyssa , Sintim Herman O. , Zhou Jie , Hayakawa Yoshihiro , Karaolis David K.R. , Gravekamp Claudia
Published: April 2023

PDF file - 146K, Figure S9: Activation of CD8 T cells by c-di-GMP-treated MDSC compared to non-treated MDSC.
Supplementary Figure 4 from STING Ligand c-di-GMP Improves Cancer Vaccination against Metastatic Breast Cancer
Authors: Chandra Dinesh , Quispe-Tintaya Wilber , Jahangir Arthee , Asafu-Adjei Denise , Ramos Ilyssa , Sintim Herman O. , Zhou Jie , Hayakawa Yoshihiro , Karaolis David K.R. , Gravekamp Claudia
Published: April 2023

PDF file - 140K, Figure S4: Effect of c-di-GMP on cell viability and cell death.
Supplementary Figure 3 from STING Ligand c-di-GMP Improves Cancer Vaccination against Metastatic Breast Cancer
Authors: Chandra Dinesh , Quispe-Tintaya Wilber , Jahangir Arthee , Asafu-Adjei Denise , Ramos Ilyssa , Sintim Herman O. , Zhou Jie , Hayakawa Yoshihiro , Karaolis David K.R. , Gravekamp Claudia
Published: April 2023

PDF file - 39K, Figure S3: High dose c-di-GMP killed 4T1 tumor cells directly.
Supplementary Figure 2 from STING Ligand c-di-GMP Improves Cancer Vaccination against Metastatic Breast Cancer
Authors: Chandra Dinesh , Quispe-Tintaya Wilber , Jahangir Arthee , Asafu-Adjei Denise , Ramos Ilyssa , Sintim Herman O. , Zhou Jie , Hayakawa Yoshihiro , Karaolis David K.R. , Gravekamp Claudia
Published: April 2023

PDF file - 77K, Figure S2: LM-Mb and c-di-GMP is effective against metastatic breast cancer in a therapeutic setting.
Supplementary Figure 1 from STING Ligand c-di-GMP Improves Cancer Vaccination against Metastatic Breast Cancer
Authors: Chandra Dinesh , Quispe-Tintaya Wilber , Jahangir Arthee , Asafu-Adjei Denise , Ramos Ilyssa , Sintim Herman O. , Zhou Jie , Hayakawa Yoshihiro , Karaolis David K.R. , Gravekamp Claudia
Published: April 2023

PDF file - 98K, Figure S1: Various immunization protocols for LM-Mb and c-di-GMP.
Supplemental Methods and Figure Legends from Extracellular Vesicles Present in Human Ovarian Tumor Microenvironments Induce a Phosphatidylserine-Dependent Arrest in the T-cell Signaling Cascade
Authors: Kelleher Raymond J. , Balu-Iyer Sathy , Loyall Jenni , Sacca Anthony J. , Shenoy Gautam N. , Peng Peng , Iyer Vandana , Fathallah Anas M. , Berenson Charles S. , Wallace Paul K. , Tario Joseph , Odunsi Kunle , Bankert Richard B.
Published: April 2023

Description of additional methods and figure legends for Supplemental Figures
Supplemental Figure S4 from Extracellular Vesicles Present in Human Ovarian Tumor Microenvironments Induce a Phosphatidylserine-Dependent Arrest in the T-cell Signaling Cascade
Authors: Kelleher Raymond J. , Balu-Iyer Sathy , Loyall Jenni , Sacca Anthony J. , Shenoy Gautam N. , Peng Peng , Iyer Vandana , Fathallah Anas M. , Berenson Charles S. , Wallace Paul K. , Tario Joseph , Odunsi Kunle , Bankert Richard B.
Published: April 2023

Fig S4. Biophysical characterization of exosomes.
Supplementary Figure 4 from Using Quantitative Seroproteomics to Identify Antibody Biomarkers in Pancreatic Cancer
Authors: Jhaveri Darshil T. , Kim Min-Sik , Thompson Elizabeth D. , Huang Lanqing , Sharma Rajni , Klein Alison P. , Zheng Lei , Le Dung T. , Laheru Daniel A. , Pandey Akhilesh , Jaffee Elizabeth M. , Anders Robert A.
Published: April 2023

Additional immunohistochemical validation showing PSMC5, MYPT1 and TFRC expression in an independent set of pancreatic cancers.
Supplementary Figure 3 from Using Quantitative Seroproteomics to Identify Antibody Biomarkers in Pancreatic Cancer
Authors: Jhaveri Darshil T. , Kim Min-Sik , Thompson Elizabeth D. , Huang Lanqing , Sharma Rajni , Klein Alison P. , Zheng Lei , Le Dung T. , Laheru Daniel A. , Pandey Akhilesh , Jaffee Elizabeth M. , Anders Robert A.
Published: April 2023

Western blots showing the antibody responses for PSMC5, MYPT1 and TFRC in patients with greater than and less than 3 years disease free survival
Supplementary Figure 2 from Using Quantitative Seroproteomics to Identify Antibody Biomarkers in Pancreatic Cancer
Authors: Jhaveri Darshil T. , Kim Min-Sik , Thompson Elizabeth D. , Huang Lanqing , Sharma Rajni , Klein Alison P. , Zheng Lei , Le Dung T. , Laheru Daniel A. , Pandey Akhilesh , Jaffee Elizabeth M. , Anders Robert A.
Published: April 2023

Selection criteria used to narrow the proteins identified in the screen to those shown in this study.
Supplemental Figure S1 from Extracellular Vesicles Present in Human Ovarian Tumor Microenvironments Induce a Phosphatidylserine-Dependent Arrest in the T-cell Signaling Cascade
Authors: Kelleher Raymond J. , Balu-Iyer Sathy , Loyall Jenni , Sacca Anthony J. , Shenoy Gautam N. , Peng Peng , Iyer Vandana , Fathallah Anas M. , Berenson Charles S. , Wallace Paul K. , Tario Joseph , Odunsi Kunle , Bankert Richard B.
Published: April 2023

Fig S1. Delipidation of ascites fluid.
Supplemental Table 1 from Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants
Authors: Krenciute Giedre , Prinzing Brooke L. , Yi Zhongzhen , Wu Meng-Fen , Liu Hao , Dotti Gianpietro , Balyasnikova Irina V. , Gottschalk Stephen
Published: April 2023

Tumor signal comparison.
Supplemental Figures 1 - 8 from Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants
Authors: Krenciute Giedre , Prinzing Brooke L. , Yi Zhongzhen , Wu Meng-Fen , Liu Hao , Dotti Gianpietro , Balyasnikova Irina V. , Gottschalk Stephen
Published: April 2023

Supplementary Figure 1: IL13Rα2-CAR and/or IL15 expression does not change T-cell phenotype. Supplementary Figure 2: Cell surface expression of IL13Rα2. Supplementary Figure 3: IL15 improves cell viability in the absence of exogenous cytokines. Supplementary Figure 4: Transgene expression is upregulated upon T cell activation. Supplemental Figure 5: IL13Rα2-CAR.IL15 T cells display activation-dependent IL15 production and greater proliferative capacity. Supplementary Figure 6: CID induces cell death in T cells genetically modified with retroviral vector encoding iC9.dNFGR.IL15. Supplemental Figure 7: Addition of exogenous IL15 increases CAR T-cell expansion in vitro. Supplementary Figure 8: IL13Rα2 or HER2 antigen loss variants are not killed by IL13Rα2- or HER2-CAR T cells.
Supplemental Figure 5 from CALGB 150905 (Alliance): Rituximab Broadens the Antilymphoma Response by Activating Unlicensed NK Cells
Authors: Du Juan , Lopez-Verges Sandra , Pitcher Brandelyn N. , Johnson Jeffrey , Jung Sin-Ho , Zhou Lili , Hsu Katharine , Czuczman Myron S. , Cheson Bruce , Kaplan Lawrence , Lanier Lewis L. , Venstrom Jeffrey M.
Published: April 2023

IL-2 stimulation of unlicensed NK cell degranulation.
Supplementary Figure S2 from Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model
Authors: Wang Lei , Amoozgar Zohreh , Huang Jing , Saleh Mohammad H. , Xing Deyin , Orsulic Sandra , Goldberg Michael S.
Published: April 2023

Supplementary Figure 2: Decitabine increases the frequency of tumor-infiltrating CD8+ T cells and CD45+ leukocytes in subcutaneous tumors.
Supplemental Figure 4 from CALGB 150905 (Alliance): Rituximab Broadens the Antilymphoma Response by Activating Unlicensed NK Cells
Authors: Du Juan , Lopez-Verges Sandra , Pitcher Brandelyn N. , Johnson Jeffrey , Jung Sin-Ho , Zhou Lili , Hsu Katharine , Czuczman Myron S. , Cheson Bruce , Kaplan Lawrence , Lanier Lewis L. , Venstrom Jeffrey M.
Published: April 2023

Proportion of CD56brightCD16dim and CD56dimCD16bright NK cells within KIR-, unlicensed, and licensed NK cell subsets.
Supplementary Table 4 from Identification of Anti-CA125 Antibody Responses in Ovarian Cancer Patients by a Novel Deep Sequence–Coupled Biopanning Platform
Authors: Frietze Kathryn M. , Roden Richard B.S. , Lee Ji-Hyun , Shi Yang , Peabody David S. , Chackerian Bryce
Published: April 2023

Supplemental Table 4. 2X2 table for CA125 and Anti-DISGTNTSRA.
Supplementary Figure 2 from Identification of Anti-CA125 Antibody Responses in Ovarian Cancer Patients by a Novel Deep Sequence–Coupled Biopanning Platform
Authors: Frietze Kathryn M. , Roden Richard B.S. , Lee Ji-Hyun , Shi Yang , Peabody David S. , Chackerian Bryce
Published: April 2023

Supplemental Figure 2. OvCa patient survival based on CA125, anti-CA125, and anti-DISGTNTSRA status at time of diagnosis.
Supplemental Table 2 from Identification of Anti-CA125 Antibody Responses in Ovarian Cancer Patients by a Novel Deep Sequence–Coupled Biopanning Platform
Authors: Frietze Kathryn M. , Roden Richard B.S. , Lee Ji-Hyun , Shi Yang , Peabody David S. , Chackerian Bryce
Published: April 2023

Supplemental Table 2. DISGTNTSRA peptide alignment with CA125/MUC16 (accession # NP_078966). Amino acid position is indicated by numerical position and alignment indicates the sequence similarity of the peptide (top) to CA125/MUC16 (bottom).
Supplementary Methods from CD4+ T Lymphocyte Ablation Prevents Pancreatic Carcinogenesis in Mice
Authors: Zhang Yaqing , Yan Wei , Mathew Esha , Bednar Filip , Wan Shanshan , Collins Meredith A. , Evans Rebecca A. , Welling Theodore H. , Vonderheide Robert H. , di Magliano Marina Pasca
Published: April 2023

PDF file - 131K, Detailed experimental procedures, lists of antibodies for immuno-staining and flow cytometry, list of primers.
Supplementary Figure 2 from CD4+ T Lymphocyte Ablation Prevents Pancreatic Carcinogenesis in Mice
Authors: Zhang Yaqing , Yan Wei , Mathew Esha , Bednar Filip , Wan Shanshan , Collins Meredith A. , Evans Rebecca A. , Welling Theodore H. , Vonderheide Robert H. , di Magliano Marina Pasca
Published: April 2023

PDF file - 686K, PanIN cells in CD4-deficient mice undergo apoptosis.
Supplemental figure legends from Altered Expression and Splicing of ESRP1 in Malignant Melanoma Correlates with Epithelial–Mesenchymal Status and Tumor-Associated Immune Cytolytic Activity
Authors: Yao Jun , Caballero Otavia L. , Huang Ying , Lin Calvin , Rimoldi Donata , Behren Andreas , Cebon Jonathan S. , Hung Mien-Chie , Weinstein John N. , Strausberg Robert L. , Zhao Qi
Published: April 2023

Figure legends for supplemental figures
Supplementary Figures 1 through 3 from Clinical Features of Acquired Resistance to Anti–PD-1 Therapy in Advanced Melanoma
Authors: Wang Daniel Y. , Eroglu Zeynep , Ozgun Alpaslan , Leger Paul D. , Zhao Shilin , Ye Fei , Luke Jason J. , Joseph Richard W. , Haq Rizwan , Ott Patrick A. , Hodi F. Stephen , Sosman Jeffrey A. , Johnson Douglas B. , Buchbinder Elizabeth I.
Published: April 2023

Supplementary Figure 1: Post-progresion survival based on initial PFS (6, 9, 12, and 15 months). Supplementary Figure 2: Radiographic example of isolated progression in one patient with acquired resistance to anti-PD-1. Supplementary Figure 3: Overall survival in the entire cohort
Supplementary Table 4 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
Authors: Hodi F. Stephen , Lawrence Donald , Lezcano Cecilia , Wu Xinqi , Zhou Jun , Sasada Tetsuro , Zeng Wanyong , Giobbie-Hurder Anita , Atkins Michael B. , Ibrahim Nageatte , Friedlander Philip , Flaherty Keith T. , Murphy George F. , Rodig Scott , Velazquez Elsa F. , Mihm Martin C. , Russell Sara , DiPiro Pamela J. , Yap Jeffrey T. , Ramaiya Nikhil , Van den Abbeele Annick D. , Gargano Maria , McDermott David
Published: April 2023

PDF file - 43K, Best overall response in ipilimumab plus bevacizumab treated patients per RECIST criteria by treatment cohort.
Supplementary Methods from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
Authors: Hodi F. Stephen , Lawrence Donald , Lezcano Cecilia , Wu Xinqi , Zhou Jun , Sasada Tetsuro , Zeng Wanyong , Giobbie-Hurder Anita , Atkins Michael B. , Ibrahim Nageatte , Friedlander Philip , Flaherty Keith T. , Murphy George F. , Rodig Scott , Velazquez Elsa F. , Mihm Martin C. , Russell Sara , DiPiro Pamela J. , Yap Jeffrey T. , Ramaiya Nikhil , Van den Abbeele Annick D. , Gargano Maria , McDermott David
Published: April 2023

PDF file - 813K, Appendix A: Clinical Protocol
Supplementary Figure Legends from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
Authors: Hodi F. Stephen , Lawrence Donald , Lezcano Cecilia , Wu Xinqi , Zhou Jun , Sasada Tetsuro , Zeng Wanyong , Giobbie-Hurder Anita , Atkins Michael B. , Ibrahim Nageatte , Friedlander Philip , Flaherty Keith T. , Murphy George F. , Rodig Scott , Velazquez Elsa F. , Mihm Martin C. , Russell Sara , DiPiro Pamela J. , Yap Jeffrey T. , Ramaiya Nikhil , Van den Abbeele Annick D. , Gargano Maria , McDermott David
Published: April 2023

PDF file - 59K
Supplementary Figure 7 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
Authors: Hodi F. Stephen , Lawrence Donald , Lezcano Cecilia , Wu Xinqi , Zhou Jun , Sasada Tetsuro , Zeng Wanyong , Giobbie-Hurder Anita , Atkins Michael B. , Ibrahim Nageatte , Friedlander Philip , Flaherty Keith T. , Murphy George F. , Rodig Scott , Velazquez Elsa F. , Mihm Martin C. , Russell Sara , DiPiro Pamela J. , Yap Jeffrey T. , Ramaiya Nikhil , Van den Abbeele Annick D. , Gargano Maria , McDermott David
Published: April 2023

PDF file - 59K, Kaplan-Meier estimates for time-to-progression in the entire treated population (A) and by treatment cohort (B). Kaplan-Meier estimates for overall survival in the entire treated population (C) and by treatment cohort (D).
Supplementary Figure 6 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
Authors: Hodi F. Stephen , Lawrence Donald , Lezcano Cecilia , Wu Xinqi , Zhou Jun , Sasada Tetsuro , Zeng Wanyong , Giobbie-Hurder Anita , Atkins Michael B. , Ibrahim Nageatte , Friedlander Philip , Flaherty Keith T. , Murphy George F. , Rodig Scott , Velazquez Elsa F. , Mihm Martin C. , Russell Sara , DiPiro Pamela J. , Yap Jeffrey T. , Ramaiya Nikhil , Van den Abbeele Annick D. , Gargano Maria , McDermott David
Published: April 2023

PDF file - 82K, Response kinetics in treated patients. Baseline tumor measurements are standardized to zero. A. Entire treatment population (cohorts 1-4). B. Cohort 2 patients (MTD). Horizontal line PD = progressive disease representing 20% increase. Horizontal line PR represents 30% decrease from baseline. Filled in circle depicts radiographic development of new sites of disease.
Supplementary Figures 1 - 6, Figure Legends from Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation
Authors: Van Allen Eliezer M. , Golay Hadrien G. , Liu Yan , Koyama Shohei , Wong Karrie , Taylor-Weiner Amaro , Giannakis Marios , Harden Maegan , Rojas-Rudilla Vanesa , Chevalier Aaron , Thai Tran , Lydon Christine , Mach Stacy , Avila Ada G. , Wong Joshua A. , Rabin Alexandra R. , Helmkamp Joshua , Sholl Lynette , Carter Scott L. , Oxnard Geoffrey , Janne Pasi , Getz Gad , Lindeman Neal , Hammerman Peter S. , Garraway Levi A. , Hodi F. Stephen , Rodig Scott J. , Dranoff Glenn , Wong Kwok-Kin , Barbie David A.
Published: April 2023

Figure S1: Orthogonal sequencing of JAK3 mutations. Figure S2: Copy number profile of tumor. Figure S3: Absolute copy number. Figure S4: PHIAL gel of patient's somatic exome results. Figure S5. Modified H-scores for tumor and immune cells. Figure S6. T cell re-activation following co-culture with JAK3-V722I expressing monocytes in the presence of MPDL3280A.
Supplemental Figures, Tables, and Legends from SLC45A2: A Melanoma Antigen with High Tumor Selectivity and Reduced Potential for Autoimmune Toxicity
Authors: Park Jungsun , Talukder Amjad H. , Lim Seon A. , Kim Kwanghee , Pan Ke , Melendez Brenda , Bradley Sherille D. , Jackson Kyle R. , Khalili Jahan S. , Wang Junmei , Creasy Caitlin , Pan Bih-Fang , Woodman Scott E. , Bernatchez Chantale , Hawke David , Hwu Patrick , Lee Kyung-Mi , Roszik Jason , Lizée Gregory , Yee Cassian
Published: April 2023

S1. Ectopic expression of HLA allotypes in melanoma cell line Mel888. S2. SLC45A2 expression is restricted to melanoma tumor cells. S3. SLC45A2 gene expression in Cancer Cell Line Encyclopedia (CCLE) cell lines. S4. Quantitative comparison of SLC45A2 gene expression in various normal tissues and cancers. S5. Generation of HLA-A*0201-restricted SLC45A2 antigen-specific CTLs from multiple normal donor PBMC. S6. SLC45A2-specific CTLs demonstrate lytic activity against uveal and mucosal melanoma cell lines. S7. IFN-gamma release by MDA-specific CTLs in response to titrated HLA-A*0201 restricted peptides. S8. Primary melanocytes express HLA-A*0201 but are only killed by SLC45A2 T cells after peptide pulsing. S9. SLC45A2-specific CTLs from different donors preferentially kill melanoma tumor cells over primary melanocytes. Supplemental Table S1.Human MDA gene primer pair sequences used for RT-PCR. Supplemental Table S2. SLC45A2-derived peptides detected by mass spectrometric analysis of melanoma cell lines. Supplemental Table S3. Confirmation of natural SLC45A2 peptide processing and presentation by HLA transduction. Supplemental Table S4.Sequences and predicted binding affinities of HLA-A2-restricted MDA peptides.
Supplementary Figure S6 from The Different T-cell Receptor Repertoires in Breast Cancer Tumors, Draining Lymph Nodes, and Adjacent Tissues
Authors: Wang Ting , Wang Changxi , Wu Jinghua , He Chenyang , Zhang Wei , Liu Jiayun , Zhang Ruifang , Lv Yonggang , Li Yongping , Zeng Xiaojing , Cao Hongzhi , Zhang Xiuqing , Xu Xun , Huang Chen , Wang Ling , Liu Xiao
Published: April 2023

The similarity between paired lymph node, non-tumor and tumor tissue.
Supplementary Figure S1 from The Different T-cell Receptor Repertoires in Breast Cancer Tumors, Draining Lymph Nodes, and Adjacent Tissues
Authors: Wang Ting , Wang Changxi , Wu Jinghua , He Chenyang , Zhang Wei , Liu Jiayun , Zhang Ruifang , Lv Yonggang , Li Yongping , Zeng Xiaojing , Cao Hongzhi , Zhang Xiuqing , Xu Xun , Huang Chen , Wang Ling , Liu Xiao
Published: April 2023

Amplification bias assessment across multiplex PCR primer mix.
Supplementary Figure Legends and Supplementary Tables 1 through 3 from The Different T-cell Receptor Repertoires in Breast Cancer Tumors, Draining Lymph Nodes, and Adjacent Tissues
Authors: Wang Ting , Wang Changxi , Wu Jinghua , He Chenyang , Zhang Wei , Liu Jiayun , Zhang Ruifang , Lv Yonggang , Li Yongping , Zeng Xiaojing , Cao Hongzhi , Zhang Xiuqing , Xu Xun , Huang Chen , Wang Ling , Liu Xiao
Published: April 2023

Supplementary Figure Legends. Table S1. The reproducibility of IHC scoring of infiltrated T cells. Table S2. The infiltration level of CD4+ and CD8+ T cells in tumors and non-tumors. Table S3. The clinical characteristics of 49 patients.
Supplementary Materials and Methods from Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors
Authors: Voena Claudia , Menotti Matteo , Mastini Cristina , Di Giacomo Filomena , Longo Dario Livio , Castella Barbara , Merlo Maria Elena Boggio , Ambrogio Chiara , Wang Qi , Minero Valerio Giacomo , Poggio Teresa , Martinengo Cinzia , D'Amico Lucia , Panizza Elena , Mologni Luca , Cavallo Federica , Altruda Fiorella , Butaney Mohit , Capelletti Marzia , Inghirami Giorgio , Jänne Pasi A. , Chiarle Roberto
Published: April 2023

Supplementary Materials and Methods
Supplementary Figure Legends from Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors
Authors: Voena Claudia , Menotti Matteo , Mastini Cristina , Di Giacomo Filomena , Longo Dario Livio , Castella Barbara , Merlo Maria Elena Boggio , Ambrogio Chiara , Wang Qi , Minero Valerio Giacomo , Poggio Teresa , Martinengo Cinzia , D'Amico Lucia , Panizza Elena , Mologni Luca , Cavallo Federica , Altruda Fiorella , Butaney Mohit , Capelletti Marzia , Inghirami Giorgio , Jänne Pasi A. , Chiarle Roberto
Published: April 2023

Supplementary Figure Legends
Supplemental Figure 2. Humoral immunity of melanoma patients to recombinant ATP6S1 protein. from Immunity to the Vacuolar ATPase Complex Accessory Unit ATP6S1 in Patients with Malignant Melanoma
Authors: Zhou Jun , Gupta Meghna , Wu Xinqi , Yoon Charles , Giobbie-Hurder Anita , Hodi F. Stephen
Published: April 2023

Antibody titers to recombinant ATP6S1 from 81 stage IV melanoma patients as determined by ELISA.
Supplementary Figures 1-4 from Environmental and Genetic Activation of Hypothalamic BDNF Modulates T-cell Immunity to Exert an Anticancer Phenotype
Authors: Xiao Run , Bergin Stephen M. , Huang Wei , Slater Andrew M. , Liu Xianglan , Judd Ryan T. , Lin En-Ju D. , Widstrom Kyle J. , Scoville Steven D. , Yu Jianhua , Caligiuri Michael A. , Cao Lei
Published: April 2023

Figure S1. Mouse characteristics prior to tumor injection and at time of sacrifice. Figure S2.Mouse physiology following EE Figure S3. Overexpressing BDNF in the hypothalamus mimics EE's effects on T cells. Figure S4. Knockdown BDNF in the hypothalamus blocks EE's effects.
Supplementary Figures S1 - S9 from Combined Anti-VEGF and Anti–CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes
Authors: Wu Xinqi , Li Jingjing , Connolly Erin M. , Liao Xiaoyun , Ouyang Jing , Giobbie-Hurder Anita , Lawrence Donald , McDermott David , Murphy George , Zhou Jun , Piesche Matthias , Dranoff Glenn , Rodig Scott , Shipp Margaret , Hodi F. Stephen
Published: April 2023

Supplementary Figure S1. Gal-1 antibodies were identified in the posttreatment plasma samples from melanoma patients on Ipi-Bev and pembrolizumab treatment. Supplementary Figure S2. Gal-1 antibody titers in pretreatment and posttreatment plasma samples from melanoma patients receiving ipilimumab and PD-1 blockade. Supplementary Figure S3. Longitudinal analyses of Gal-1 antibody responses to Ipi-Bev in metastatic melanoma patients. Supplementary Figure S4. Purification of recombinant human Gal-1 with His, biotinylated Avi, and SUMO tags at the N terminus (HAS-Gal-1). Supplementary Figure S5. Enrichment of Gal-1 antibodies from patient plasma. Supplementary Figure S6. Binding of Gal-1 to CD45. Supplementary Figure S7. Immunohistochemistry of Gal-1 expression in pretreatment and posttreatment tumor biopsies of patients on Ipi-Bev therapy. Supplementary Figure S8. Kaplan-Meier survival curves of patients based on pretreatment circulating Gal-1 levels. Supplementary Figure S9. Kaplan-Meier survival curves of patients based on circulating Gal-1 fold changes as a result of ipilimumab treatment.
Supplementary Table S1 from Neoantigen Load, Antigen Presentation Machinery, and Immune Signatures Determine Prognosis in Clear Cell Renal Cell Carcinoma
Authors: Matsushita Hirokazu , Sato Yusuke , Karasaki Takahiro , Nakagawa Tohru , Kume Haruki , Ogawa Seishi , Homma Yukio , Kakimi Kazuhiro
Published: April 2023

Non-synonymous mutations and prognosis of 97 ccRCC patients
Supplementary Table S2 from 4-1BB–Enhanced Expansion of CD8+ TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8+ T Cells
Authors: Harao Michiko , Forget Marie-Andrée , Roszik Jason , Gao Hui , Babiera Gildy V. , Krishnamurthy Savitri , Chacon Jessica A. , Li Shumin , Mittendorf Elizabeth A. , DeSnyder Sarah M. , Rockwood Korrene F. , Bernatchez Chantale , Ueno Naoto T. , Radvanyi Laszlo G. , Vence Luis , Haymaker Cara , Reuben James M.
Published: April 2023

BC9 peptides
Supplementary Figures S1-S5 from STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients
Authors: Srivastava Raghvendra M. , Trivedi Sumita , Concha-Benavente Fernando , Hyun-bae Jie , Wang Lin , Seethala Raja R. , Branstetter Barton F. , Ferrone Soldano , Ferris Robert L.
Published: April 2023

Supplementary figure S1. JHU-029 HNC cells were left untreated or were treated for 48h with the EGFR inhibitor mAb cetuximab (10 mg/ml). Supplementary figure S2. JHU-029 were treated (48h), with cetuximab (10 mg/ml), IFNg (10 U/ml), cetuximab plus IFNg (10 mg/ml, 10 U/ml) and transcript level of SHP2 was analyzed with qPCR. Supplementary figure S3. JHU-029 (A-B), and PCI-13(C-D), cells were treated with control siRNA, EGFR siRNA, control siRNA plus cetuximab, and EGFR siRNA plus cetuximab, and levels of EGFR (A and C), and HLA class I (B and D), were determined by FACS. Supplementary figure S4. JHU-029 were treated (48h), with cetuximab (10 mg/ml), IFNg (10 U/ml), cetuximab plus IFNg (10 mg/ml, 10 U/ml) and transcript level of TAP1 (A), and LMP2 (B), were analyzed with qPCR. Supplementary figure S5. Characterization of HLA-A2:MAGE-3 complex mAb.
Supplementary Materials and Methods and Supplementary Figures 1-5 from Therapeutic HPV Cancer Vaccine Targeted to CD40 Elicits Effective CD8+ T-cell Immunity
Authors: Yin Wenjie , Duluc Dorothée , Joo HyeMee , Xue Yaming , Gu Chao , Wang Zhiqing , Wang Lei , Ouedraogo Richard , Oxford Lance , Clark Amelia , Parikh Falguni , Kim-Schulze Seunghee , Thompson-Snipes LuAnn , Lee Sang-Yull , Beauregard Clay , Woo Jung-Hee , Zurawski Sandra , Sikora Andrew G. , Zurawski Gerard , Oh SangKon
Published: April 2023

Supplementary Materials and Methods: This section includes additional Materials and Methods. Supplementary Figure S1: Specificity and binding ability of αCD40 (12E12) antibody. Supplementary Figure S2. αCD40-HPV16.E6/7 can target CD40 and can thus bind to human DCs and B cells. Supplementary Figure S3. αCD40-HPV16.E6/7 can induce E6/7-specific CD8+ and CD4+ T cell responses in vivo. Supplementary Figure S4. Poly(I:C) effectively enhances antigen-specific CD8+ T cell response in human in vitro. Supplementary Figure S5. Poly(I:C) effectively enhances antigen-specific CD8+ T cell response in CD40Tg mice in vivo.
Supplementary Figure 5 from Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
Authors: Shen Li , Sundstedt Anette , Ciesielski Michael , Miles Kiersten Marie , Celander Mona , Adelaiye Remi , Orillion Ashley , Ciamporcero Eric , Ramakrishnan Swathi , Ellis Leigh , Fenstermaker Robert , Abrams Scott I. , Eriksson Helena , Leanderson Tomas , Olsson Anders , Pili Roberto
Published: April 2023

Supplementary Figure 5. The effect of tasquinimod treatment on CD11c+ dendritic cells.
Supplemental Figure 6 from Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors
Authors: Wang Enxiu , Wang Liang-Chuan , Tsai Ching-Yi , Bhoj Vijay , Gershenson Zack , Moon Edmund , Newick Kheng , Sun Jing , Lo Albert , Baradet Timothy , Feldman Michael D. , Barrett David , Puré Ellen , Albelda Steven , Milone Michael C.
Published: April 2023

FAP-specific KIR-CAR/Dap12 T cells induce bone marrow hypocellularity and loss of body weight.
Supplementary Figure 1 from Programmed Cell Death Ligand 1 Expression in Osteosarcoma
Authors: Shen Jacson K. , Cote Gregory M. , Choy Edwin , Yang Pei , Harmon David , Schwab Joseph , Nielsen G. Petur , Chebib Ivan , Ferrone Soldano , Wang Xinhui , Wang Yangyang , Mankin Henry , Hornicek Francis J. , Duan Zhenfeng
Published: April 2023

PDF file - 40K, Supplementary Figure S1. Antibodies that failed to show sufficient specificity for PD-L1 by flow cytometry.
Figure S3 from VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma
Authors: Wu Xinqi , Giobbie-Hurder Anita , Liao Xiaoyun , Lawrence Donald , McDermott David , Zhou Jun , Rodig Scott , Hodi F. Stephen
Published: April 2023

Supplementary Figure S3. Qualitative analysis of effect of Ipi-Bev on serum cytokines/chemokines.
Supplemental Figure 5 from Gp96-Ig/Costimulator (OX40L, ICOSL, or 4-1BBL) Combination Vaccine Improves T-cell Priming and Enhances Immunity, Memory, and Tumor Elimination
Authors: Fromm George , de Silva Suresh , Giffin Louise , Xu Xin , Rose Jason , Schreiber Taylor H.
Published: April 2023

Supplemental Figure 5 supports main Figure 5 and provides additional data on the SIINFEKL+ and FoxP3+ cells detected in the peritoneal cavity and TIL in the B16.F10-Ova model system.
Supplementary Table 1 from Tumor Subtype-Specific Cancer–Testis Antigens as Potential Biomarkers and Immunotherapeutic Targets for Cancers
Authors: Yao Jun , Caballero Otavia L. , Yung W.K. Alfred , Weinstein John N. , Riggins Gregory J. , Strausberg Robert L. , Zhao Qi
Published: April 2023

XLSX file - 14K, Supplemental Table S1. CT genes used in this study.
Supplementary Figure Legends from A Rapid Embryonic Stem Cell–Based Mouse Model for B-cell Lymphomas Driven by Epstein–Barr Virus Protein LMP1
Authors: Ba Zhaoqing , Meng Fei-Long , Gostissa Monica , Huang Pei-Yi , Ke Qiang , Wang Zhe , Dao Mai N. , Fujiwara Yuko , Rajewsky Klaus , Zhang Baochun , Alt Frederick W.
Published: April 2023

Supplementary Figure Legends
Supplemental Figure 1 from PD-1 Restrains Radiotherapy-Induced Abscopal Effect
Authors: Park Sean S. , Dong Haidong , Liu Xin , Harrington Susan M. , Krco Christopher J. , Grams Michael P. , Mansfield Aaron S. , Furutani Keith M. , Olivier Kenneth R. , Kwon Eugene D.
Published: April 2023

Supplemental Figure 1. Synergistic effects of PD-1 and CTLA-4 blockade in enhancing antitumor abscopal effects.
Supplementary Figures from Development of Aggressive Pancreatic Ductal Adenocarcinomas Depends on Granulocyte Colony Stimulating Factor Secretion in Carcinoma Cells
Authors: Pickup Michael W. , Owens Philip , Gorska Agnieszka E. , Chytil Anna , Ye Fei , Shi Chanjuan , Weaver Valerie M. , Kalluri Raghu , Moses Harold L. , Novitskiy Sergey V.
Published: April 2023

Supplemental Figures 1-3
Supplementary Figure Legend from Experimental Lung Metastases in Mice Are More Effectively Inhibited by Blockade of IL23R than IL23
Authors: Yan Juming , Allen Stacey , Vijayan Dipti , Li Xian-Yang , Harjunpää Heidi , Takeda Kazuyoshi , Liu Jing , Cua Daniel J. , Smyth Mark J. , Teng Michele W.L.
Published: April 2023

Supplementary Figure Legends
Supplemental Figure Legends from TUSC2 Immunogene Therapy Synergizes with Anti–PD-1 through Enhanced Proliferation and Infiltration of Natural Killer Cells in Syngeneic Kras-Mutant Mouse Lung Cancer Models
Authors: Meraz Ismail M. , Majidi Mourad , Cao Xiaobo , Lin Heather , Li Lerong , Wang Jing , Baladandayuthapani Veera , Rice David , Sepesi Boris , Ji Lin , Roth Jack A.
Published: April 2023

S1. Gating strategy of peripheral blood leukocytes and splenocytes was shown to determine immune subpopulations for multi-color flow cytometry assay. S2. Effect of NK depletion antibody (NK1.1) on other immune cells. S3. Effect of CD8 T depletion on other immune cells. S4. NanoString gene expression analysis in tumor microenvironment.
Supplemental Data from Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade
Authors: Ariyan Charlotte E. , Brady Mary Sue , Siegelbaum Robert H. , Hu Jian , Bello Danielle M. , Rand Jamie , Fisher Charles , Lefkowitz Robert A. , Panageas Kathleen S. , Pulitzer Melissa , Vignali Marissa , Emerson Ryan , Tipton Christopher , Robins Harlan , Merghoub Taha , Yuan Jianda , Jungbluth Achim , Blando Jorge , Sharma Padmanee , Rudensky Alexander Y. , Wolchok Jedd D. , Allison James P.
Published: April 2023

Supplementary Figure 1. Gemcitabine and CTLA-4 blockade synergize to create an inflammatory microenvironment and anti-tumor response. Mice with palpable tumors were treated with low dose gemcitabine followed by systemic CTLA-4 blockade. Survival was improved (A) and tumors with combination treatment had a significant influx in CD4 and CD8 Tcells (B). Elispot (C) demonstrated improved enhanced IFNγ in response to SPAS-1 peptide (SNC9H8). Supplemental Figure S2. Lack of significant change of TIM3 or LAG3 over time in peripheral blood mononuclear cells (PBMC) over time. Supplementary Table S1. Toxicities in the limb according to Wieberdink criteria Supplemental Table 2. Nanostring fold change results of all genes
Supplementary Table 2 from CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8+ T Cell–Relevant Genes
Authors: Aznar M. Angela , Labiano Sara , Diaz-Lagares Angel , Molina Carmen , Garasa Saray , Azpilikueta Arantza , Etxeberria Iñaki , Sanchez-Paulete Alfonso R. , Korman Alan J. , Esteller Manel , Sandoval Juan , Melero Ignacio
Published: April 2023

DNA methylation array results with 6B4 antiCD137 mAb
Tables S1-S7 from The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity
Authors: Danilova Ludmila , Anagnostou Valsamo , Caushi Justina X. , Sidhom John-William , Guo Haidan , Chan Hok Yee , Suri Prerna , Tam Ada , Zhang Jiajia , Asmar Margueritta El , Marrone Kristen A. , Naidoo Jarushka , Brahmer Julie R. , Forde Patrick M. , Baras Alexander S. , Cope Leslie , Velculescu Victor E. , Pardoll Drew M. , Housseau Franck , Smith Kellie N.
Published: April 2023

Supplementary Tables containing information pertaining to the viral epitopes evaluated, expanded clonotypes, clonotypes detected in pentamer-sorted populations, and the MANAs evaluated in patient JH124
Supplementary Figure 1 from The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity
Authors: Danilova Ludmila , Anagnostou Valsamo , Caushi Justina X. , Sidhom John-William , Guo Haidan , Chan Hok Yee , Suri Prerna , Tam Ada , Zhang Jiajia , Asmar Margueritta El , Marrone Kristen A. , Naidoo Jarushka , Brahmer Julie R. , Forde Patrick M. , Baras Alexander S. , Cope Leslie , Velculescu Victor E. , Pardoll Drew M. , Housseau Franck , Smith Kellie N.
Published: April 2023

This contains the figure and legend showing clonotypic expansions after 10 and 20 days
Supplementary Methods and Figure Legends from USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity
Authors: Huang Xing , Zhang Qi , Lou Yu , Wang Junli , Zhao Xinyu , Wang Lin , Zhang Xiaozhen , Li Shanshan , Zhao Yulan , Chen Qi , Liang Tingbo , Bai Xueli
Published: April 2023

Supplementary Materials and Methods, and Supplementary Figure legends.
Figure S1 from Assessing the Magnitude of Immunogenic Cell Death Following Chemotherapy and Irradiation Reveals a New Strategy to Treat Pancreatic Cancer
Authors: Ye Jian , Mills Bradley N. , Zhao Tony , Han Booyeon J. , Murphy Joseph D. , Patel Ankit P. , Johnston Carl J. , Lord Edith M. , Belt Brian A. , Linehan David C. , Gerber Scott A.
Published: April 2023

Supplemental figure 1
Supplementary Figures and Tables from An IL6–Adenosine Positive Feedback Loop between CD73+ γδTregs and CAFs Promotes Tumor Progression in Human Breast Cancer
Authors: Hu Guoming , Cheng Pu , Pan Jun , Wang Shimin , Ding Qiannan , Jiang Zhou , Cheng Lu , Shao Xuan , Huang Liming , Huang Jian
Published: April 2023

Supplemental Figures 1-12 and Supplementary Tables 1-3
Supplementary Figure Legends from CD47 Expression Defines Efficacy of Rituximab with CHOP in Non–Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL
Authors: Bouwstra Renée , He Yuan , de Boer Janneke , Kooistra Hilde , Cendrowicz Ewa , Fehrmann Rudolf S.N. , Ammatuna Emanuele , zu Eulenburg Christine , Nijland Marcel , Huls Gerwin , Bremer Edwin , van Meerten Tom
Published: April 2023

Supplementary Figure Legends
Figure S1, S2, S3, S4 from CD47 Expression Defines Efficacy of Rituximab with CHOP in Non–Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL
Authors: Bouwstra Renée , He Yuan , de Boer Janneke , Kooistra Hilde , Cendrowicz Ewa , Fehrmann Rudolf S.N. , Ammatuna Emanuele , zu Eulenburg Christine , Nijland Marcel , Huls Gerwin , Bremer Edwin , van Meerten Tom
Published: April 2023

Supplemental Figure 1. (A) Kaplan Meijer curves for patients with high or low CD47 expression treated with CHOP or R-CHOP. (B) Kaplan Meijer curves for DLBCL patients treated with CHOP or R-CHOP Supplemental Figure 2. (A) non-GCB have significantly higher CD47 expression level than GCB DLBCL patients. (B) CHOP and R-CHOP treated patients have similar CD47 expression levels. Supplemental Figure 3. (A) Kaplan Meijer curves for DLBCL patients divided by their cell-of-origin (COO, Germinal Center B-cells (GCB) or non-GCB). (B,C) Kaplan Meijer curves to study the effect of rituximab to CHOP chemotherapy in non-GCB and GCB DLBCL patients, respectively. (D) Kaplan Meijer estimates for DLBCL patients sorted on CD47 expression level and COO. Non-GCB DLBCL Patients with high CD47 expression have an inferior survival. Supplemental Figure 4. (A) Cell lines were mixed with macrophages and treated with human IgG4 isotype control antibody.
Supplementary Table S1 from TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer
Authors: Han Jiefei , Duan Jianchun , Bai Hua , Wang Yuqi , Wan Rui , Wang Xin , Chen Si , Tian Yanhua , Wang Di , Fei Kailun , Yao Zhuoran , Wang Shuhang , Lu Zhimin , Wang Zhijie , Wang Jie
Published: April 2023

Details on the genes included in the 1021 gene panel in next-generation sequencing (NGS).
Figure S4 from Virus-Like Particle–Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens
Authors: Kines Rhonda C. , Thompson Cynthia D. , Spring Sean , Li Zhenyu , de los Pinos Elisabet , Monks Stephen , Schiller John T.
Published: April 2023

Gating examples for the in vivo markers for AU-011 induced immunogenic cell death.
Supplementary Tables from Overproduction of Gastrointestinal 5-HT Promotes Colitis-Associated Colorectal Cancer Progression via Enhancing NLRP3 Inflammasome Activation
Authors: Li Tao , Fu Bin , Zhang Xin , Zhou Yunjiang , Yang Mengdi , Cao Mengran , Chen Yaxin , Tan Yingying , Hu Rong
Published: April 2023

Supplementary Tables includes tables for shRNA sequences, primers sequences, and reagents used in this study.
Supplementary Figures from Overproduction of Gastrointestinal 5-HT Promotes Colitis-Associated Colorectal Cancer Progression via Enhancing NLRP3 Inflammasome Activation
Authors: Li Tao , Fu Bin , Zhang Xin , Zhou Yunjiang , Yang Mengdi , Cao Mengran , Chen Yaxin , Tan Yingying , Hu Rong
Published: April 2023

Supplementary figures contains 10 figures with figure legends for extensional data presentation.
Supplemental Figures 1-8 from The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity
Authors: Palakurthi Sangeetha , Kuraguchi Mari , Zacharek Sima J. , Zudaire Enrique , Huang Wei , Bonal Dennis M. , Liu Jeffrey , Dhaneshwar Abha , DePeaux Kristin , Gowaski Martha R. , Bailey Dyane , Regan Samuel N. , Ivanova Elena , Ferrante Catherine , English Jessie M. , Khosla Aditya , Beck Andrew H. , Rytlewski Julie A. , Sanders Catherine , Laquerre Sylvie , Bittinger Mark A. , Kirschmeier Paul T. , Packman Kathryn , Janne Pasi A. , Moy Christopher , Wong Kwok-Kin , Verona Raluca I. , Lorenzi Matthew V.
Published: April 2023

Supplemental Figures 1-8
Supplementary Data from XCL1/Glypican-3 Fusion Gene Immunization Generates Potent Antitumor Cellular Immunity and Enhances Anti–PD-1 Efficacy
Authors: Chen Kun , Wu Zhiyuan , Zhao Hong , Wang Yanmei , Ge Yutong , Wang Dongmei , Li Zhengjiang , An Changming , Liu Yuying , Wang Feifei , Bi Xinyu , Wang Hongying , Cai Jianqiang , Ma Chunhong , Qu Chunfeng
Published: April 2023

Supplementary Tables 1-2 and Supplementary Figures 1-8
Supplemental Figures 1-8 from Targeting PIM1-Mediated Metabolism in Myeloid Suppressor Cells to Treat Cancer
Authors: Xin Gang , Chen Yao , Topchyan Paytsar , Kasmani Moujtaba Y. , Burns Robert , Volberding Peter J. , Wu Xiaopeng , Cohn Alexandra , Chen Yiliang , Lin Chien-Wei , Ho Ping-Chih , Silverstein Roy , Dwinell Michael B. , Cui Weiguo
Published: April 2023

Supplemental Figures 1-8 plus Legends
Supplementary Tables and Figures from Antitumor T-cell Immunity Contributes to Pancreatic Cancer Immune Resistance
Authors: Ajina Reham , Malchiodi Zoe X. , Fitzgerald Allison A. , Zuo Annie , Wang Shangzi , Moussa Maha , Cooper Connor J. , Shen Yue , Johnson Quentin R. , Parks Jerry M. , Smith Jeremy C. , Catalfamo Marta , Fertig Elana J. , Jablonski Sandra A. , Weiner Louis M.
Published: April 2023

Supplementary Tables 1-7 and Figures 1-17
Table S2 from Disrupting LILRB4/APOE Interaction by an Efficacious Humanized Antibody Reverses T-cell Suppression and Blocks AML Development
Authors: Gui Xun , Deng Mi , Song Hao , Chen Yuanzhi , Xie Jingjing , Li Zunling , He Licai , Huang Fangfang , Xu Yixiang , Anami Yasuaki , Yu Hai , Yu Chenyi , Li Leike , Yuan Zihao , Xu Xiaoying , Wang Qihui , Chai Yan , Huang Tao , Shi Yi , Tsuchikama Kyoji , Liao X. Charlene , Xia Ningshao , Gao George F. , Zhang Ningyan , Zhang Cheng Cheng , An Zhiqiang
Published: April 2023

Interaction between h128-3 Fab and LILRB4.
Supplementary Table 1 from Long-term Sculpting of the B-cell Repertoire following Cancer Immunotherapy in Patients Treated with Sipuleucel-T
Authors: Zhang Li , Kandadi Harini , Yang Hai , Cham Jason , He Tao , Oh David Y. , Sheikh Nadeem A. , Fong Lawrence
Published: April 2023

Comparison of the proportions of pairwise overlapping BCR clones present at both earlier time point (T1) and later time point (T2) between treated and naïve patients. The proportion of overlapping BCR clones was calculated by the number of the overlapping clones divided by the total number of clones presented at either time point, i.e., the Jaccard index. Bold text highlights significant differences between treated and naïve patients (Wilcoxon sum rank test p < 0.05).